Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
- 31 December 2007
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 31 (12) , 1737-1740
- https://doi.org/10.1016/j.leukres.2007.05.020
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood, 2006
- TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative stateLeukemia, 2005
- Inhibition of Akt Kinase Activity by a Peptide Spanning the βA Strand of the Proto-oncogene TCL1Journal of Biological Chemistry, 2004
- Human chronic lymphocytic leukemia modeled in mouse by targetedTCL1expressionProceedings of the National Academy of Sciences, 2002
- The role of TCL1 in human T-cell leukemiaOncogene, 2001
- The Protooncogene TCL1 Is an Akt Kinase CoactivatorMolecular Cell, 2000
- Deregulated expression of TCL1 causes T cell leukemia in miceProceedings of the National Academy of Sciences, 1998